Activation of cytolytic activity in peripheral blood
- 30 September 1993
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 55 (3) , 380-385
- https://doi.org/10.1002/ijc.2910550307
Abstract
Our purpose was to evaluate the ability of blood monocytes of renal cancer patients to become cytotoxic against fresh, autologous tumor cells. Fresh target cells were obtained by mechanical and enzymatic dissociation of tumor and normal renal tissue. The A375 cell line, derived from a human melanoma, and the SW626 cell line, derived from a human ovarian carcinoma, were used as positive target cell controls. Monocytes from renal cancer patients and normal volunteers were activated in vitro with lipopolysaccharide (LPS), or muramyl tripeptide (MTP-PE), or multilamellar vesicle liposomes containing MTP-PE (MLV-MTP-PE), with or without a pre-incubation with r-IFN-γ, and tested for cytotoxicity in a 72-hr 111Indium-release assay. All patients were tumor-free at the time of the monocyte study. No difference in cytotoxic activity was observed between monocytes from healthy volunteers and those from cancer patients. Freshly dissociated tumor cells were as susceptible to tumoricidal monocytes as the 2 cell lines. Moreover, no cell population appeared to be resistant to activated monocytes, which were cytotoxic to both allogeneic and autologous fresh tumor cells. Activated monocytes maintained their ability to discriminate between normal and neoplastic cells and were not cytotoxic against autologous or allogeneic normal non-neoplastic cells. Our data indicate that MLV MTP-PE liposomes activate peripheral blood monocytes from cancer patients to a tumoricidal status against fresh, dissociated non-cultured autologous tumor cells.Keywords
This publication has 16 references indexed in Scilit:
- Decreased monocyte-mediated cytostasis of human cancer cell in patients with lung cancerCancer Immunology, Immunotherapy, 1985
- The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues.The Journal of Immunology, 1983
- Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity.The Journal of Experimental Medicine, 1983
- Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic diseaseSpringer Seminars in Immunopathology, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: Augmentation by interferon, lymphokines and endotoxinInternational Journal of Cancer, 1981
- Measurement of macrophage-mediated cytotoxicity against adherent and non-adherent target cells by release of 111indium-oxineJournal of Immunological Methods, 1981
- Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proceedings of the National Academy of Sciences, 1981
- DEFECTIVE MONOCYTE KILLING IN PATIENTS WITH MALIGNANCIES AND RESTORATION OF FUNCTION DURING CHEMOTHERAPYThe Lancet, 1980
- Cytolytic and cytostatic activity on tumor cells of circulating human monocytesInternational Journal of Cancer, 1979